Momelotinib access expanded for myelofibrosis patients in Long-Term safety study

NCT ID NCT03441113

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study provides extended access to the drug momelotinib for 237 people with a type of bone marrow cancer called myelofibrosis. Participants had already been taking momelotinib in earlier studies and had not seen their disease get worse. The goal is to see how safe the drug is over a longer period and whether it helps people live longer without the disease getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: momelotinib (a drug taken as a tablet once daily)
What this could lead to: If successful, this could confirm momelotinib as a safe long-term treatment option for people with myelofibrosis, helping control the disease and improve survival.
What could go wrong: This is an extended-access study, not a new treatment test. It only includes people who already tolerated the drug, so results may not apply to all patients. Long-term risks are still being monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF) POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) PRIMARY MYELOFIBROSIS PRIMARY MYELOFIBROSIS (PMF)

Contacts and locations

Locations

GSK Investigational Site

Scottsdale, Arizona, 53226, United States
GSK Investigational Site

Orange, California, 97239, United States
GSK Investigational Site

Stanford, California, 94305-5821, United States
GSK Investigational Site

Aurora, Colorado, 80045, United States
GSK Investigational Site

Jacksonville, Florida, 32224, United States
GSK Investigational Site

Tampa, Florida, 33612, United States
GSK Investigational Site

Atlanta, Georgia, 30322, United States
GSK Investigational Site

Baltimore, Maryland, 21229-5299, United States
GSK Investigational Site

Boston, Massachusetts, 02215, United States
GSK Investigational Site

Rochester, Minnesota, 55905, United States
GSK Investigational Site

St Louis, Missouri, 63130, United States
GSK Investigational Site

Hackensack, New Jersey, 07601, United States
GSK Investigational Site

The Bronx, New York, 10467, United States
GSK Investigational Site

Cleveland, Ohio, 44195, United States
GSK Investigational Site

South Brisbane, Queensland, 4101, Australia
GSK Investigational Site

Bedford Park, South Australia, 5000, Australia
GSK Investigational Site

Frankston, Victoria, 31 99, Australia
GSK Investigational Site

Melbourne, Victoria, 3004, Australia
GSK Investigational Site

Melbourne, Victoria, 3050, Australia
GSK Investigational Site

Perth, Western Australia, 6000, Australia
GSK Investigational Site

Linz, 4020, Austria
GSK Investigational Site

Vienna, 1090, Austria
GSK Investigational Site

Antwerp, 2030, Belgium
GSK Investigational Site

Bruges, 8000, Belgium
GSK Investigational Site

Leuven, 3000, Belgium
GSK Investigational Site

Liège, 4000, Belgium
GSK Investigational Site

Pleven, 5800, Bulgaria
GSK Investigational Site

Rousse, 7002, Bulgaria
GSK Investigational Site

Sofia, 01431, Bulgaria
GSK Investigational Site

Sofia, 1756, Bulgaria
GSK Investigational Site

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site

Montreal, Quebec, H3H 2R9, Canada
GSK Investigational Site

Montreal, Quebec, H3T 1E2, Canada
GSK Investigational Site

Aalborg, 9000, Denmark
GSK Investigational Site

Herlev, 2100, Denmark
GSK Investigational Site

Le Mans, 72037, France
GSK Investigational Site

Lille, 13273, France
GSK Investigational Site

Marseille, 13273, France
GSK Investigational Site

Paris, 75475, France
GSK Investigational Site

Pessac, 33604, France
GSK Investigational Site

Pierre-Bénite, 69495, France
GSK Investigational Site

Toulouse, 31059, France
GSK Investigational Site

Aachen, 52074, Germany
GSK Investigational Site

Cologne, 50937, Germany
GSK Investigational Site

Dresden, 01307, Germany
GSK Investigational Site

Halle, 06120, Germany
GSK Investigational Site

Leipzig, 04103, Germany
GSK Investigational Site

Lübeck, 79106, Germany
GSK Investigational Site

Mainz, 55131, Germany
GSK Investigational Site

Budapest, 1083, Hungary
GSK Investigational Site

Budapest, 1097, Hungary
GSK Investigational Site

Debrecen, 4032, Hungary
GSK Investigational Site

Győr, 9024, Hungary
GSK Investigational Site

Kaposvár, 7400, Hungary
GSK Investigational Site

Nyíregyháza, 4400, Hungary
GSK Investigational Site

Tatabánya, 2800, Hungary
GSK Investigational Site

Afula, 18101, Israel
GSK Investigational Site

Ashkelon, 7830604, Israel
GSK Investigational Site

Haifa, 3436212, Israel
GSK Investigational Site

Jerusalem, 9112001, Israel
GSK Investigational Site

Kfar Saba, 44281, Israel
GSK Investigational Site

Bologna, 40138, Italy
GSK Investigational Site

Florence, 50134, Italy
GSK Investigational Site

Genova, 16132, Italy
GSK Investigational Site

Milan, 20122, Italy
GSK Investigational Site

Monza, 20900, Italy
GSK Investigational Site

Naples, 80131, Italy
GSK Investigational Site

Pesaro, 61122, Italy
GSK Investigational Site

Rionero in Vulture PZ, 85028, Italy
GSK Investigational Site

Roma, 00161, Italy
GSK Investigational Site

Torino, 10126, Italy
GSK Investigational Site

Torino, 10128, Italy
GSK Investigational Site

Verona, 37134, Italy
GSK Investigational Site

Maastricht, 6229 ER, Netherlands
GSK Investigational Site

Brzozów, 36-200, Poland
GSK Investigational Site

Chorzów, 41-500, Poland
GSK Investigational Site

Gdansk, 80-214, Poland
GSK Investigational Site

Krakow, 30-688, Poland
GSK Investigational Site

Lublin, 20-081, Poland
GSK Investigational Site

Opole, 45-061, Poland
GSK Investigational Site

Poznan, 60-631, Poland
GSK Investigational Site

Brasov, 500152, Romania
GSK Investigational Site

Bucharest, 022328, Romania
GSK Investigational Site

Bucharest, 030171, Romania
GSK Investigational Site

Cluj-Napoca, 400124, Romania
GSK Investigational Site

Craiova, 200143, Romania
GSK Investigational Site

Iași, 700111, Romania
GSK Investigational Site

Singapore, 169608, Singapore
GSK Investigational Site

Singapore, 188770, Singapore
GSK Investigational Site

Busan, 48108, South Korea
GSK Investigational Site

Daegu, 700-721, South Korea
GSK Investigational Site

Seoul, 03080, South Korea
GSK Investigational Site

Seoul, 03722, South Korea
GSK Investigational Site

Seoul, 135-710, South Korea
GSK Investigational Site

Seoul, 137-701, South Korea
GSK Investigational Site

Barcelona, 08003, Spain
GSK Investigational Site

Barcelona, 08035, Spain
GSK Investigational Site

Barcelona, 08916, Spain
GSK Investigational Site

Madrid, 28034, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28222, Spain
GSK Investigational Site

Pamplona, 31008, Spain
GSK Investigational Site

Zaragoza, 50012, Spain
GSK Investigational Site

Kaohsiung City, 807, Taiwan
GSK Investigational Site

Kaohsiung City, 833, Taiwan
GSK Investigational Site

Taipei, 100, Taiwan
GSK Investigational Site

Taoyuan, 333, Taiwan
GSK Investigational Site

Airdrie, ML6 0JS, United Kingdom
GSK Investigational Site

Bristol, BS2 8ED, United Kingdom
GSK Investigational Site

Cardiff, CF14 4XW, United Kingdom
GSK Investigational Site

London, W12 0HS, United Kingdom
GSK Investigational Site

Oxford, OX3 7LE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.